Current diabetes reviews最新文献

{"title":"The Impact of Yoga as an Adjunct to Standard Care on Glycemic Control, Insulin Resistance, Oxidative Stress, and Quality of Life in Individuals with or at Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","authors":"Danish Javed, Madhu Bhargavi, Varun Malhotra, Sophia Mudda, R Padmavathi, Vishnu Vardhan Karrothu, Madhu Babu Adusumilli, Santenna Chenchula","doi":"10.2174/0115733998383494250827215758","DOIUrl":"https://doi.org/10.2174/0115733998383494250827215758","url":null,"abstract":"<p><strong>Introduction: </strong>Type 2 Diabetes Mellitus (T2DM) is marked by insulin resistance and chronic hyperglycemia. Yoga, a complementary therapy, may improve metabolic outcomes when used with standard care. This systematic review and meta-analysis aimed to evaluate the effects of yoga on glycemic control, insulin resistance, oxidative stress, and psychological well-being in individuals with or at risk of T2DM.</p><p><strong>Methods: </strong>We conducted a systematic search in PubMed, CAM-QUEST®, and the Cochrane Central Register following PRISMA guidelines. We included randomized controlled trials (RCTs) assessing yoga interventions (asanas, pranayama, kriyas, and meditation) alongside standard care. Primary outcomes were fasting blood glucose (FBS), postprandial blood glucose (PPBS), HbA1c, serum insulin, and HOMA-IR. Secondary outcomes included oxidative stress markers (glutathione, malondialdehyde [MDA], superoxide dismutase [SOD]) and psychological outcomes. Meta-analyses were conducted using random-effects models in RevMan 5.4.1.</p><p><strong>Results: </strong>Fourteen RCTs (n = 1,629 participants) were included. Yoga combined with standard care significantly improved FBS (SMD = -1.60; 95% CI: -2.27 to -0.92), PPBS (SMD = -2.16; p = 0.03), HbA1c (SMD = -0.92; 95% CI: -1.59 to -0.26), and HOMA-IR (SMD = -1.28; p = 0.002). MDA levels were significantly reduced, though glutathione and SOD showed no significant changes. Psychological well-being improved in several trials.</p><p><strong>Discussion: </strong>Yoga appears effective in improving glycemic outcomes and insulin resistance in patients with or at risk of T2DM. It may also reduce oxidative stress and enhance psychological well- being, highlighting its potential as a holistic intervention.</p><p><strong>Conclusion: </strong>Yoga, when integrated with standard care, offers clinically relevant benefits in managing T2DM and related metabolic risks. Further high-quality, multi-centered trials using standardized protocols are needed to validate and generalize these findings.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Importance of miRNA in Diabetic Neuropathy: Pathophysiology, Diagnosis, and Therapeutic Potential.","authors":"Desh Deepak Singh","doi":"10.2174/0115733998375284250905115146","DOIUrl":"https://doi.org/10.2174/0115733998375284250905115146","url":null,"abstract":"<p><p>Diabetic Neuropathy (DN) is the major chronic complication in diabetic patients. Exact pathophysiological mechanisms of DN are not explored well, although axon Schwann cell and microvascular endothelial communication network failure play a major contributing role in DN. The multiple pathophysiological mechanisms of DN are regulated by microRNAs (miRNAs), including inflammation, vascularization, angiogenesis, posttranscriptional regulation, intercellular communication, and signalling pathways. Various types of miRNA affect the gene expressions within cells, but their profiles often change during DN, including SMAD, PI3K, NF-KB, and MAPK. DN has been associated with the miRNAs-9, miRNA-106, miRNA-182, miRNA-23a, miRNA- 23b, miRNA-23c, miRNA-503, miRNA-203, miRNA-145, and miRNA-126. MiRNA dysregulation is one of the first molecular changes seen in diabetics. Therefore, miRNAs have potential as therapeutic targets and biomarkers. This study aims to discuss the importance of miRNA in clinical pathophysiology, diagnosis, signalling pathways, and therapeutic targets for DN.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Insulin Resistance: Diagnosis and Management.","authors":"Yu-Lan Wu, Xin Wang, Wei-Wei Zhang, Dan Feng, Xie Luo","doi":"10.2174/0115733998390048250902113845","DOIUrl":"https://doi.org/10.2174/0115733998390048250902113845","url":null,"abstract":"<p><p>Insulin resistance is an endocrine disorder associated with various diseases, including diabetes, metabolic syndrome, cardiovascular diseases, and cancer. However, severe insulin resistance differs significantly from common insulin resistance regarding the causes and treatment approaches. Severe insulin resistance is a group of rare disorders characterized by hyperglycemia and hyperinsulinemia, with or without hypoglycemia, along with various metabolic abnormalities and diverse clinical manifestations. Owing to their rarity and complexity, these conditions can be easily misdiagnosed as common diabetes and are often overlooked. Severe insulin resistance is typically reported in individual case studies, lacking comprehensive summaries. This article provides a detailed overview of the different types of severe insulin resistance based on the specific sites of insulin signaling defects. It includes pre-receptor signaling defects, such as insulin autoimmune syndrome, which results from insulin autoantibodies; receptor-level insulin resistance syndromes, including type A and type B insulin resistance syndromes; and post-receptor signaling defects, such as lipodystrophy syndrome. We describe the causes, clinical symptoms, diagnosis, and treatment of extreme insulin resistance and differentiate between these diseases. In this review, we aim to assist physicians in identifying the causes of severe insulin resistance early and in providing individualized treatment for patients, ultimately improving clinical outcomes.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","authors":"Lexie Bai, Delong Liu, Ning Su, Lina Zhang, Zhiyong Yang","doi":"10.2174/0115733998359708250822102217","DOIUrl":"https://doi.org/10.2174/0115733998359708250822102217","url":null,"abstract":"<p><strong>Introduction: </strong>Clinical trials indicate that IDegLira is effective in treating type 2 diabetes mellitus (T2DM). This study aims to assess the efficacy and safety of IDegLira in type 2 diabetes mellitus (T2DM) comprehensively.</p><p><strong>Methods: </strong>To identify relevant randomized controlled trials, we searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov. Risk Ratios (RR) and 95% Confidence Intervals (CI) were calculated using the Mantel-Haenszel approach for dichotomous outcomes. Mean Difference (MD) and 95% CI calculated by the inverse variance approach were applied to continuous outcomes.</p><p><strong>Results: </strong>Twelve randomized controlled trials involving 7628 participants were included in this study. Compared with control groups, IDegLira has a significant hypoglycemic effect in reducing hemoglobin A1c (MD = -0.66; 95% CI [-0.85, -0.47]; p < 0.00001), fasting plasma glucose (MD = -0.90; 95% CI [-1.40, -0.41]; p = 0.0003), self-measured plasma glucose (MD = -0.82; 95% CI [-1.22, -0.42]; p < 0.0001) and achieving the hemoglobin A1c level of < 7.0%(RR = 1.66; 95% CI [1.44, 1.92]; p < 0.00001) or < 6.5% (RR = 2.13; 95% CI [1.76, 2.57]; p < 0.00001). IDegLira outperforms insulin in achieving the target of HbA1c < 7.0 or < 6.5% without hypoglycemia and weight gain. Besides, IDegLira did not increase the incidence of adverse events and serious adverse events.</p><p><strong>Discussion: </strong>In this section, IDegLira's benefits on simultaneously achieving glycemic control, weight loss, and reduced hypoglycemia risk were summarized. The statistical results were carefully interpreted in conjunction with clinical concerns regarding T2DM complications, adverse effects, and cost-effectiveness differences. An expanded discussion was conducted on integrating individualized HbA1c goals as a dual endpoint, without increasing body weight or the risk of hypoglycemia. Finally, the limitations of the present study are indicated.</p><p><strong>Conclusions: </strong>IDegLira exhibits a favorable glycemic control effect and acceptable adverse effects in Type 2 Diabetes Mellitus (T2DM). Superior performance in the target glycemic control, particularly suitable for T2DM patients who do not reach the target hemoglobin A1c and have comorbid CVD or obesity.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feimin in Glucose Homeostasis: Mechanistic Insights, Population Heterogeneity, and Therapeutic Potential.","authors":"Sijun Yang","doi":"10.2174/0115733998418887250826055154","DOIUrl":"https://doi.org/10.2174/0115733998418887250826055154","url":null,"abstract":"<p><p>The recent discovery of feimin, a feeding-induced myokine modulating glucose homeostasis via the MERTK pathway, offers a novel therapeutic avenue for metabolic disorders. While other studies delineate its acute metabolic effects in Han Chinese populations, critical gaps remain in understanding its mechanistic interplay, population generalizability, and long-term impacts. This perspective synthesizes current evidence, highlights limitations in study design and translational applicability, and proposes integrative approaches, spanning multi-omics, global consortia, and interventional trials, to unravel feimin's role in metabolic regulation. By addressing these challenges, feimin may emerge as a biomarker or therapeutic target for diabetes and related syndromes.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the Landscape of Epigenetic Research in Diabetes Mellitus: A Decade-Long Bibliometric Analysis (2014-2024).","authors":"Yu'e Tang, Huan Zhu, Lele Liu, Xiuying Guo, Qianbo Zhang, Yuhe Dai, Junqi Yang, Rifang Gu, Jidong Rong, Xuqiang Nie","doi":"10.2174/0115733998389913250807044815","DOIUrl":"https://doi.org/10.2174/0115733998389913250807044815","url":null,"abstract":"<p><strong>Background: </strong>Epigenetic regulation constitutes critical molecular mechanisms underlying the pathogenesis of diabetes and disease progression. While substantial mechanistic investigations exist, the field lacks systematic mapping of research trends, collaborative networks, and emerging frontiers.</p><p><strong>Objectives: </strong>To conduct the first comprehensive bibliometric evaluation of epigenetic studies in diabetes mellitus and its complications (2014-2024), identifying key research domains, international collaboration patterns, and innovative investigative directions to inform strategic research planning and highlight opportunities for innovative therapeutic approaches.</p><p><strong>Methods: </strong>We interrogated the Web of Science Core Collection using stringent inclusion criteria, analyzing 1,451 publications through advanced multi-dimensional metrics in CiteSpace (6.2.R4), VOSviewer (1.6.20), and Bibliometrix (4.1.3).</p><p><strong>Results: </strong>A total of 1,451 original and review articles were retrieved, involving 83 countries/regions, 576 journals, and 7,645 authors. The United States produced the highest number of publications (n = 464), followed by China (n = 283) and Italy (n = 121). The International Journal of Molecular Sciences was the leading journal (66 publications), dominated by review articles (n = 53). Author collaboration networks were extensive, with Charlotte Ling emerging as the most prolific and influential author in publications, citations, and H-index. Keyword co-occurrence analyses emphasized type 2 DM, gestational DM, and diabetic nephropathy as primary research focuses, while new frontiers highlighted potential links to Alzheimer's disease and fibroblast biology.</p><p><strong>Conclusion: </strong>This multi-dimensional analysis provides quantitative visualization of research evolution, delineates current investigative priorities, and highlights underexplored therapeutic targets. Our findings establish a strategic framework for transdisciplinary collaboration in precision diabetology.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preface.","authors":"Robert P Hoffman","doi":"10.2174/0115733998435469250819041021","DOIUrl":"https://doi.org/10.2174/0115733998435469250819041021","url":null,"abstract":"","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nano-curcumin for the Treatment and Management of Diabetes Mellitus.","authors":"Bhagavathi Sundaram Sivamaruthi, Chaiyavat Chaiyasut, Kaliyappan Illakiya, Periyanaina Kesika","doi":"10.2174/0115733998400703250729191528","DOIUrl":"https://doi.org/10.2174/0115733998400703250729191528","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is a growing global health concern, placing increasing strain on healthcare systems. Curcumin, the primary bioactive compound in Curcuma longa (turmeric), has been reported to exhibit several therapeutic effects, including potential benefits for managing DM. However, its clinical use is limited by poor bioavailability. Nanotechnology, particularly nano-curcumin (nCUR), offers a promising solution by enhancing curcumin's delivery and effectiveness. Preclinical and clinical studies suggest that nCUR may help manage DM and its complications by reducing oxidative stress, genotoxicity, and mitochondrial dysfunction. Despite these promising results, the exact molecular mechanisms of nCUR remain unclear, and clinical evidence is still limited. Furthermore, there is a lack of global guidelines regulating the use of nanomaterials in medicine. In summary, while nCUR shows strong potential as a therapeutic option for diabetes, further research is necessary to elucidate its mechanisms, confirm its clinical efficacy and safety, and establish standardized guidelines for its use in healthcare.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms and Interventions of Diabetic Wound Healing.","authors":"Juan Feng, Sien Lai, Dongsheng Tang","doi":"10.2174/0115733998356905250706203510","DOIUrl":"https://doi.org/10.2174/0115733998356905250706203510","url":null,"abstract":"<p><p>Diabetic wounds constitute a significant global health challenge, affecting millions of individuals worldwide and imposing a substantial burden on healthcare systems. This review explores the complex pathophysiology of diabetic wound healing and discusses innovative interventions aimed at addressing this critical clinical problem. The impaired healing process in diabetic wounds is characterized by a multitude of interrelated factors, including cellular dysfunction, altered inflammatory responses, oxidative stress, the formation of advanced glycation end-products, and neurovascular abnormalities. Fibroblasts, keratinocytes, and endothelial cells demonstrate diminished proliferation and migration capabilities, while immune cells exhibit dysregulated responses, which contribute to a persistent inflammatory state. Complications associated with diabetes, such as neuropathy and vascular insufficiency, further exacerbate the wound healing process. Recent advancements in wound care strategies have opened new avenues for enhancing diabetic wound healing. These advancements encompass the development of advanced dressings and biomaterials, growth factor therapies, cell-based interventions, and gene therapy approaches. The integration of diverse treatment modalities, coupled with the management of systemic metabolic abnormalities, offers significant promise for improving outcomes in diabetic wound care. Future research should focus on optimizing combination therapies, developing personalized treatment algorithms, and conducting large-scale clinical trials to establish the most effective and safest interventions for diabetic wound healing.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review on Diabulimia: Exploring the Intersection of Disordered Eating, Eating Disorders, Insulin Dose Manipulation, and Type 1 Diabetes.","authors":"Velimir Altabas, Jelena Marinković Radošević, Nika Grubiješić","doi":"10.2174/0115733998347278250309180707","DOIUrl":"https://doi.org/10.2174/0115733998347278250309180707","url":null,"abstract":"<p><strong>Background: </strong>Although insulin is essential for managing type 1 diabetes and is life-saving for patients with this condition, some individuals may intentionally reduce or omit insulin due to a fear of weight gain or a desire to lose weight. This behavior is commonly referred to as diabulimia.</p><p><strong>Methods: </strong>Since diabulimia is not formally defined, a systematic review of the limited literature was conducted on November 8th, 2024, using PubMed, Scopus, and Web of Science databases. The search terms included \"diabulimia\", \"insulin omission\", \"insulin restriction\", \"eating disorders\", \"disordered eating\", and \"type 1 diabetes\". Out of 288 manuscripts, 19 were selected after excluding non-English articles and screening the titles and abstracts.</p><p><strong>Results: </strong>Eating disorders and disordered eating are common in patients with type 1 diabetes, often driven by concerns regarding body image and weight. These behaviors can complicate diabetes management, worsen glucose control, and increase the risk of complications. Diabulimia may develop as a coping mechanism, especially in adolescents with higher body mass index and a history of eating disorders. Diagnosis is challenging due to the lack of established guidelines, but poor glucose control can raise suspicion and prompt further psychological evaluation. A multidisciplinary approach, combining medical care, nutrition, mental health support, and therapy, is recommended, despite limited evidence.</p><p><strong>Conclusion: </strong>While diabulimia is not formally recognized, understanding its impact can help healthcare professionals diagnose and manage it more effectively, improving patients' health and well-being.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}